^
    Evidence Level:
    Sensitive: A1 - Approval

    [HER-2 overexpression-Gastroesophageal Junction Adenocarcinoma-trastuzumab-anns]

    Source:
    FDA
    Test:

    HercepTest, HER2 IQFISH pharmDx

    Published date:
    06/13/2019
    Excerpt:
    KANJINTI is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.
    Secondary therapy:
    CF; XP
    Evidence Level:
    Sensitive: A1 - Approval

    [HER-2 overexpression-Gastric Cancer-trastuzumab-anns]

    Source:
    FDA
    Test:

    HercepTest, HER2 IQFISH pharmDx

    Published date:
    06/13/2019
    Excerpt:
    KANJINTI is a HER2/neu receptor antagonist indicated for:...the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma….Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product...
    Secondary therapy:
    ;
    Evidence Level:
    Sensitive: A1 - Approval

    [HER-2 positive-HER2 Positive Breast Cancer-trastuzumab + pertuzumab]

    Source:
    FDA
    Test:

    HercepTest

    Excerpt:
    PERJETA is a HER2/neu receptor antagonist indicated for:...Use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
    Secondary therapy:
    docetaxel
    Evidence Level:
    Sensitive: A1 - Approval

    [HER-2 positive-HER2 Positive Breast Cancer-trastuzumab + pertuzumab]

    Source:
    FDA
    Test:

    HercepTest

    Excerpt:
    PERJETA is a HER2/neu receptor antagonist indicated for:...Use in combination with trastuzumab and chemotherapy as...neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer....adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence...
    Evidence Level:
    Sensitive: A1 - Approval

    [HER-2 overexpression-Gastric Cancer-trastuzumab]

    Source:
    FDA
    Test:

    HercepTest

    Excerpt:
    Herceptin is a HER2/neu receptor antagonist indicated for...The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
    Evidence Level:
    Sensitive: A1 - Approval

    [HER-2 overexpression-Breast Cancer-trastuzumab-anns]

    Source:
    FDA
    Test:

    HercepTest, HER2 IQFISH pharmDx

    Excerpt:
    KANJINTI is a HER2/neu receptor antagonist indicated for: the treatment of HER2 overexpressing breast cancer.
    Secondary therapy:
    paclitaxel; paclitaxel + doxorubicin hydrochloride + cyclophosphamide; carboplatin + docetaxel; docetaxel + doxorubicin hydrochloride + cyclophosphamide
    Evidence Level:
    Sensitive: C3 – Early Trials

    [ER positive-HER2 Negative Breast Cancer-exemestane]

    Source:
    J Nippon Med Sch
    Test:

    HercepTest

    Title:
    Optimal treatment duration of neoadjuvant endocrine therapy in women aged 60 years or older with estrogen receptor-positive, HER2-negative invasive breast cancer
    Published date:
    11/30/2020
    Excerpt:
    Inclusion criteria were women aged ≥ 60 years with Stage II or III breast cancer classified as estrogen receptor–positive / human epidermal growth factor receptor 2–negative….Patients took exemestane 25 mg per day for at least 3 years after starting the treatment unless progression was observed....Of all 24 patients, the maximal response was identified in 18 (75%).
    DOI:
    https://doi.org/10.1272/jnms.jnms.2021_88-509
    Evidence Level:
    Resistant: C3 – Early Trials

    [HER-2 amplification-Colorectal Cancer-cetuximab]

    Source:
    Cancer Discov
    Test:

    HercepTest

    Title:
    A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
    Excerpt:
    Therefore, the prevalence of HER2 amplification increased from 2% to 3% to more than 36% (4/11) when we considered cases resistant to cetuximab that were wild-type for KRAS, NRAS, BRAF, and PIK3CA.
    DOI:
    10.1158/2159-8290.CD-11-0109